Key Takeaways
- Revenue down 40% YoY, but QoQ recovery underway: Revenue from operations fell to ₹192.4 crore, driven by destocking and supply chain realignment, though a 16% QoQ increase signals the contrast media dispatches are normalizing.
- Margins compressed by one-offs and mix: Gross margin dipped to 52% and EBITDA margin to 24%, hit by a one-time inventory write-off, labor code costs, and foreign consultant fees, layered on top of operating deleverage from lower sales.
- The growth narrative is shifting to FY27: Management pointed to two major lines (a cardiovascular molecule and a contrast media NCE intermediate) backed by customer orders, plus a backward integration play, as the engines for a better FY27.
- A ₹1,000 crore Vizag bet signals long-term confidence: The board approved a greenfield project aligned with specific customer demand, not speculative capacity, with Phase-1 focused on new API and intermediate products.
- What to watch next quarter: Whether the destocking in pharma intermediates truly ends, any concrete update on the “encouraging” new API/PI product, and specific FY27 CAPEX targets.
Financial Performance & Margin Drivers
- YoY decline, QoQ recovery: The 40% YoY revenue drop was driven by channel inventory destocking and supply chain realignment for Bempedoic acid, while the 16% QoQ increase came from recognizing contrast media dispatches that were in transit last quarter.
- Gross margin swing explained: Last quarter’s 65% gross margin was inflated by goods in transit; when that revenue was booked this quarter, the associated inventorized overhead released, causing a dip to 52%. A one-time inventory write-off and slight saccharin price erosion added marginal pressure.
- EBITDA margin hit by three one-offs: Beyond operating deleverage from lower sales, the 24% EBITDA margin absorbed the impact of a labor code implementation, engagement of a foreign consultant (a recurring, strategic expense for European-based transformation help), and the inventory write-off.
- Trade receivables spike is launch-related: The increase is normal when filling the channel for a new product launch, a critical step in the pharmaceutical world.
- Nine-month view is healthier: For the nine months ended December, revenue grew 3% YoY and gross margin improved to 53% from 50%, driven by product mix in the PI segment.
Shiven Arora: "Both of them would be positively contributing for FY27, which is backed by some customer orders. And you have seen in the past year, we have been able to scale up both the molecules well."
Product & Pipeline Dynamics
- Contrast media normalization: The Q2 to Q3 swing was a cut-off timing issue, not volume or pricing pressure. Q3 dispatches are at a steady-state, and the closing cut-off will be recognized in Q4. The gadolinium-based NCE has reached a steady-state, with the end-molecule growing high-teens.
- Two contrast media needle movers: An advanced intermediate for an existing product is under validation with five years of capacity ready, and an NCE intermediate on a new line (commenced December 2024) has performed well over the past 12 months.
- Bempedoic acid destocking: Channel inventory destocking and supply chain realignment are subduing orders; management believes it may take a couple of quarters to completely realign. The end molecule is still showing good mid-level two-digit growth, with new markets like Japan opening up.
- Pharma intermediates decline is transitional: The destocking is at the end of its transition, with a nine-to-ten-month lag from supply to purchase; recovery to a normal, potentially better run rate may take a quarter or two.
- Iodinated contrast media launch in FY27: The commercial launch will happen in FY27 with a ramp-up from Q1; value per kg will be higher than the main molecule because it is forward integration.
- New sweetener pipeline: Exhibit batches of a new artificial sweetener will be initiated in FY27, targeting a capacity of about 10% of a $1 billion market; pilot quantities will provide indicators for continuous engineering.
VK Singh: "It is not that supplies from Blue Jet are not going and somebody else is supplying. Or the end molecule is not doing well. So it is neither the case."
CDMO & Late-Stage Pipeline
- R&D infrastructure doubling: Over the last 18 months, the company doubled its R&D infrastructure and talent pool, and is investing about ₹40 crores in a new Hyderabad R&D center focused on GLP-1 intermediates, peptide chemistry, bio-catalysis, and faster CDMO turnaround. Development work is expected to commence from Q3 FY27.
- CDMO pipeline tracking 20 active RFPs: Six are high-conviction Phase-3 programs, including a couple of GLP-1 candidates and one contrast media NCE. Two are commercial products that may evolve into strategic lateral entries with dedicated capacity planning.
- Late-stage assets timeline: About six late-stage assets are expected to start contributing in about two years. Two lateral entries are in very advanced conversations, with capacities envisaged at Vizag to cater to these opportunities.
- Customer engagement ramp-up: The company is onboarding a senior resource in Europe to strengthen customer engagement, complementing the foreign consultants already helping with strategy and transformation.
- New API/PI product teased: Management stated there is “something very encouraging cooking” in the API/PI basket, with a positive update promised for the next quarter, but declined to provide any details now.
Shiven Arora: "There is something very encouraging cooking, but I think we would be in a position to share that in the next quarter."
Capacity Expansion & Capital Allocation
- Vizag Greenfield Project: The board approved a ₹1,000 crore investment over three to four years for a greenfield site, with a groundbreaking ceremony scheduled this month. Phase-1 will set up dedicated capacity for APIs and intermediates focused on new products aligned with specific customer requirements, not capacity creation in anticipation.
- Mahad Unit-3 nearing completion: The core block, designed for a key side chain in the contrast media portfolio, is on track for validations in Q1 FY27. Cumulative CAPEX incurred to date is approximately ₹146 crores. This backward integration play is described as a potential significant strategic needle mover on both top and bottom lines.
- Funding strategy: The initial phase of the Vizag CAPEX will be funded through internal accruals. The company has options for debt markets, capital markets, and co-investment with customers, and noted it has headroom to offload shares to meet the minimum promoter stake of 75%.
- No significant near-term P&L impact from Vizag: Most expenses will be capitalized, so the project is not expected to materially pressure the profit and loss statement in the near term.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Contrast media commercial launch | Iodinated contrast media product launch and ramp-up | FY27, from Q1 onwards |
| Mahad Unit-3 qualification | Core block ready for validations | Q1 FY27 |
| Hyderabad R&D center operational | Development work to commence | Q3 FY27 |
| New sweetener exhibit batches | Pilot quantities to be produced for continuous engineering indicators | FY27 |
| Late-stage asset contribution | About six late-stage assets to start contributing | Approximately two years from now |
| Destocking realignment | Channel inventory and supply chain for Bempedoic acid to normalize | A couple of quarters |
| New API/PI product update | Positive update to be shared | Next quarter |
| FY27 CAPEX targets | Specific targets to be provided | Next quarter |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue from operations | ₹192.4 cr, decreased 40% YoY from ₹318.4 cr |
| Revenue from operations QoQ | +16%, increase mainly from contrast media dispatches recognized |
| Gross margin | 52%, lower than normal trend due to product mix and one-time inventory write-off |
| EBITDA margin | 24%, lower due to operating leverage, labor code implementation, and foreign consultants |
| EBITDA | decreased 62% YoY |
| PAT | decreased 39% YoY |
| Nine months revenue from operations | +3% YoY, increase due to higher PI sales |
| Nine months gross margin | 53%, compared to 50% last year |
| Nine months other income | ₹4.5 cr |
| Cumulative CAPEX at Mahad Unit-3 | approx. ₹146 cr incurred to-date |
| Vizag Greenfield total investment plan | ₹1,000 cr over next three to four years |
| New Hyderabad R&D center investment | about ₹40 cr |
| Cash balance | ₹410 cr as of December |
| Active RFPs tracked | around 20, including six high conviction phase-3 programs |
| Power from renewable sources | 70% of consumption met through wind and solar |